Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 04:01 ET | Source: Research and Markets

Bone Metastasis in Solid Tumors Market Research and Global Long-term Forecast Report 2025-2035 Featuring Mabwell Bioscience, Novartis, Telix Pharmaeuticals, Sichuan Kelun-Biotech

Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Bone Metastasis in Solid Tumors Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035" report has been added to ...
April 21, 2026 07:00 ET | Source: LeonaBio, Inc.

Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data

BOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high...
April 16, 2026 13:12 ET | Source: Wake Radiology UNC Health Rex

Wake Radiology "Steps Up to the Plate" for Susan G. Komen Triangle Race for the Cure

Wake Radiology UNC Health Rex announces its continued support for Susan G. Komen® by sponsoring the upcoming 2026 Komen Triangle Race for the Cure.
April 15, 2026 02:30 ET | Source: Tensive

Tensive publishes positive interim pivotal clinical data showing REGENERA™ supports natural breast reconstruction in Updates in Surgery

Advanced biomaterial device designed for use in lumpectomy surgeries Interim results from the first 25 of 94 patients at 6 months follow upConfirms REGENERA™ is safe and biocompatible as breast tissue...
April 08, 2026 07:00 ET | Source: Incyclix Bio

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
March 30, 2026 04:28 ET | Source: Research and Markets

Cancer Clinical Decision Tools Market to Grow by $280 Million During 2026-2030: Key Growth Areas & Competitive Strategies Identified

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cancer Clinical Decision Tools Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global cancer clinical decision tools...
March 27, 2026 10:49 ET | Source: Research and Markets

Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players

Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Market Report 2026" has been added to ResearchAndMarkets.com's offering. The anti-cancer monoclonal antibodies (mAbs) market has...
March 26, 2026 17:10 ET | Source: LeonaBio, Inc.

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer...
March 17, 2026 05:53 ET | Source: BCC Research LLC

Global Market for Oncology Biosimilars Set to Surge at 12.6% CAGR Through 2030

“Global Oncology Biosimilars Market” is projected to grow from $9.6 billion in 2025 to $17.5 billion by the end of 2030, at a CAGR of 12.6%.
March 11, 2026 11:10 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Io Therapeutics reports publication of studies on its RXR agonist compound for prevention of Triple Negative Breast Cancer.